ArticleCancers2024

Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium.

Anupam Verma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.